Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: a look ahead at potential oncology blockbuster approvals; strong data for Mirati’s KRAS contender in colorectal cancer; Keytruda’s architect reflects in its great success; Amgen’s waiting game for ChemoCentryx; and a look at dynamics in China’s sizzling immuno-oncology market.

Scrip Five Must Know Things
audio roundup of selected content from Scrip's global team over the past week

More from Archive

More from Scrip